Reply: Are we overestimating LSM-based HCC risk in MASLD? Addressing immortal time bias.
APA
John BV, Bastaich D, Dahman B (2025). Reply: Are we overestimating LSM-based HCC risk in MASLD? Addressing immortal time bias.. Hepatology (Baltimore, Md.). https://doi.org/10.1097/HEP.0000000000001563
MLA
John BV, et al.. "Reply: Are we overestimating LSM-based HCC risk in MASLD? Addressing immortal time bias.." Hepatology (Baltimore, Md.), 2025.
PMID
41061099
같은 제1저자의 인용 많은 논문 (5)
- Alpha-1 Antitrypsin Deficiency in Patients With Cirrhosis in a US National Cohort.
- Hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease with increased alcohol intake (MetALD).
- Association of Glucagon-Like Peptide-1 Receptor Agonists With Liver-Related Outcomes and All-Cause Mortality in Patients With Harmful Alcohol Use: A Target Trial Emulation Study.
- Use of liver stiffness measurement for HCC risk stratification in metabolic dysfunction-associated steatotic liver disease.
- Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD.